BridgeBio Pharma (NASDAQ:BBIO) announces
that it was unable to come to an agreement to acquire the outstanding
common stock of its subsidiary Eidos Therapeutics (NASDAQ:EIDX) that BridgeBio does not already own (~34% of Eidos’s outstanding shares).
Subsequent to an initial offer of 1.3 BridgeBio
shares for each Eidos share, the offer was raised twice, resulting in a
final offer equivalent to 1.5 BridgeBio shares for each Eidos share with
an option for Eidos shareholders to receive a portion of that
consideration in cash.
https://seekingalpha.com/news/3505455-bridgebio-terminates-merger-process-eidos-therapeutics
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.